Benjamin Edwards Inc Crispr Therapeutics Ag Transaction History

Benjamin Edwards Inc

$8.36 Billion
Q3 2025

A detailed history of Benjamin Edwards Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Benjamin Edwards Inc holds 54,220 shares of CRSP stock, worth $3.92 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

54,220

Previous 57,760 6.13%

Holding current value

$3.92 Million

Previous $2.81 Million 25.06%

% of portfolio

0.04%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 23, 2025	SELL	$48.51 - $68.14 $171,725 - $241,215	-3,540 Reduced 6.13%	54,220 $3.51 Million
Q2 2025 Aug 14, 2025	BUY	$31.27 - $48.64 $214,043 - $332,940	6,845 Added 13.44%	57,760 $2.81 Million
Q1 2025 May 12, 2025	BUY	$34.03 - $53.02 $199,177 - $310,326	5,853 Added 12.99%	50,915 $1.73 Million
Q4 2024 Feb 14, 2025	BUY	$38.65 - $55.15 $477,675 - $681,598	12,359 Added 37.79%	45,062 $1.77 Million
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $1.45 Million - $2.04 Million	32,465 Added 13640.76%	32,703 $1.54 Million
Q2 2024 Aug 12, 2024	SELL	$51.17 - $68.18 $6,703 - $8,931	-131 Reduced 35.5%	238 $13,000
Q1 2024 Apr 29, 2024	BUY	$60.67 - $89.12 $1,820 - $2,673	30 Added 8.85%	369 $25,000
Q4 2023 Feb 06, 2024	SELL	$38.62 - $72.18 $6,372 - $11,909	-165 Reduced 32.74%	339 $21,000
Q3 2023 Nov 13, 2023	BUY	$45.39 - $59.0 $590 - $767	13 Added 2.65%	504 $23,000
Q2 2023 Aug 15, 2023	SELL	$43.47 - $67.77 $2,912 - $4,540	-67 Reduced 12.01%	491 $28,000
Q1 2023 Apr 27, 2023	BUY	$41.0 - $56.12 $1,230 - $1,683	30 Added 5.68%	558 $25,000
Q4 2022 Feb 07, 2023	BUY	$39.19 - $65.67 $4,193 - $7,026	107 Added 25.42%	528 $21,000
Q3 2022 Oct 28, 2022	SELL	$61.1 - $83.78 $4,765 - $6,534	-78 Reduced 15.63%	421 $28,000
Q2 2022 Aug 12, 2022	BUY	$43.23 - $73.83 $821 - $1,402	19 Added 3.96%	499 $30,000
Q1 2022 May 04, 2022	BUY	$53.19 - $79.24 $531 - $792	10 Added 2.13%	480 $30,000
Q4 2021 Feb 07, 2022	BUY	$70.09 - $111.29 $5,186 - $8,235	74 Added 18.69%	470 $36,000
Q3 2021 Nov 02, 2021	SELL	$110.2 - $156.64 $1,542 - $2,192	-14 Reduced 3.41%	396 $44,000
Q2 2021 Aug 11, 2021	SELL	$100.84 - $161.89 $6,857 - $11,008	-68 Reduced 14.23%	410 $66,000
Q1 2021 May 14, 2021	SELL	$110.72 - $210.04 $7,418 - $14,072	-67 Reduced 12.29%	478 $58,000
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $18,563 - $40,362	-233 Reduced 29.95%	545 $83,000
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $3,768 - $4,830	48 Added 6.58%	778 $65,000
Q1 2020 May 07, 2020	BUY	$33.68 - $62.53 $3,671 - $6,815	109 Added 17.55%	730 $31,000
Q4 2019 Feb 06, 2020	BUY	$36.68 - $73.13 $1,980 - $3,949	54 Added 9.52%	621 $38,000
Q3 2019 Nov 05, 2019	BUY	$40.99 - $52.56 $860 - $1,103	21 Added 3.85%	567 $23,000
Q2 2019 Aug 08, 2019	BUY	$35.45 - $48.2 $9,500 - $12,917	268 Added 96.4%	546 $26,000
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $7,789 - $11,361	278 New	278 $10,000

Others Institutions Holding CRSP

# of Institutions

543

Shares Held

68.7M

Call Options Held

3.67M

Put Options Held

2.25M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $5.64B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

News

Stay updated on Benjamin Edwards Inc with notifications on news.

Account

Benjamin Edwards Inc Crispr Therapeutics Ag Transaction History